Home
June 2008 July 2008 August 2008
Su Mo Tu We Th Fr Sa
Week 27 1 2 3 4 5
Week 28 6 7 8 9 10 11 12
Week 29 13 14 15 16 17 18 19
Week 30 20 21 22 23 24 25 26
Week 31 27 28 29 30 31

Ketorolac Effectively Inhibits Ureteral Contractility In Vitro - Abstract Show Comments PDF Print E-mail
  
Monday, 24 March 2008

Division of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.

The use of ketorolac in the management of painful symptoms associated with urinary stones is well supported in the literature; however, the gastric and renal adverse effects limit the dose and duration of administration. As a nonselective cyclooxygenase inhibitor, ketorolac can act locally to help control renal colic by inhibiting smooth muscle contractions and inflammation. We sought to confirm ketorolac's inhibition of ureteral contractility and determine a dose response relationship to identify an effectiveness range.

Porcine ureter strips attached to force displacement transducers were suspended in organ tissue baths that contained aerated Krebs buffer. Tissues equilibrated for 1 hour, and a spontaneous contractility rate was established. Tissues were incubated with a concentration-response curve of ketorolac (0.1 nM-10 muM) for 90 minutes and compared with indomethacin (1 muM) and dimethyl sulfoxide (DMSO) 0.1%. Contractility rates were recorded on a polygraph and analyzed for changes over exposure time.

Ketorolac inhibition of ureteral contractility was dose dependent. At 90 minutes, the average percent decrease from the spontaneous contraction rate for 0.1 nM ketorolac was 18.2%; 1 nM, 34.3%; 10 nM, 56.0%; 100 nM, 69.9%; 1 muM, 88.7%; and 10 muM, 98.3%. Ureteral contractility was significantly reduced by 1 muM ketorolac (39.0%; P = 0.016) at 15 minutes when compared with DMSO. In addition, 1 muM ketorolac was not significantly different at any time point from any of the higher doses studied.

Ketorolac inhibition of stretch-induced ureteral contractility is concentration-dependent between 1 nM and 1 muM. Local administration of ketorolac at these doses may be useful during the management of stones while at the same time limiting the risk for adverse effects.

Written by
Wen CC, Coyle TL, Jerde TJ, Nakada SY.

Reference
J Endourol. 2008 Mar 6. Epub ahead of print.
doi:10.1089/end.2007.9839

PubMed Abstract
PMID:18324898

UroToday.com Urolithiasis Section

Reader Comments

Please log-in or register in order to submit comments.

Powered by AkoComment!

 
User Rating: / 0
PoorBest


 
< Prev   Next >